Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 6% – Here’s Why

Posted by George Bondi on Aug 4th, 2026

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report)’s stock price was down 6% on Tuesday . The stock traded as low as $43.11 and last traded at $43.22. 1,415,651 shares traded hands during trading, an increase of 89% from the average daily volume of 749,782 shares. The stock had previously closed at $46.00.

Supernus Pharmaceuticals News Roundup

Here are the key news stories impacting Supernus Pharmaceuticals this week:

Positive Sentiment: Supernus reported second-quarter revenue of $219.1 million, up 32% year over year, supported by growth in Qelbree, ONAPGO and ZURZUVAE collaboration revenue. The company raised full-year revenue guidance to $860 million-$890 million and adjusted operating earnings guidance to $150 million-$180 million. Supernus Announces Second Quarter 2026 Financial Results
Positive Sentiment: The all-stock merger with Indivior is expected to create a diversified CNS company with approximately $2.2 billion in annual revenue, $888 million of pro forma adjusted EBITDA and $125 million in annual cost synergies. The combined company is expected to retain the Supernus name and ticker, with Jack Khattar as CEO. Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge
Neutral Sentiment: ONAPGO sales reached $13.5 million and Supernus remains on track to seek FDA approval for a second supplier in the third quarter of 2026. However, investors will likely continue to monitor the product’s launch trajectory and pipeline execution.
Negative Sentiment: The merger terms give Indivior shareholders approximately 56.5% of the combined company, while Supernus shareholders receive 1.5401 Indivior shares per SUPN share. Indivior will also pay a $1 billion special dividend financed partly by $650 million of new debt, raising concerns about dilution, leverage and whether Supernus investors receive sufficient value.
Negative Sentiment: Supernus posted a $58.4 million quarterly net loss, or $1.01 per share, primarily because of a $54.9 million non-cash APOKYN impairment. Full-year GAAP operating-loss guidance was also reduced to $20 million-$50 million, even though adjusted guidance increased.
Negative Sentiment: Merger approval, integration and synergy realization remain uncertain. Several shareholder law firms have announced investigations into whether the transaction provides a fair price, adding potential litigation and execution risk. Recent insider activity also shows 17 sales and no purchases over six months.

Analyst Ratings Changes

Several equities research analysts recently weighed in on SUPN shares. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $62.83.

Get Our Latest Analysis on Supernus Pharmaceuticals

Supernus Pharmaceuticals Stock Performance

The business’s 50-day moving average is $46.22 and its 200-day moving average is $49.05. The company has a market capitalization of $2.51 billion, a PE ratio of -84.80, a PEG ratio of 0.95 and a beta of 0.56.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. lifted its stake in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares during the period. Torren Management LLC purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth $51,000. Hantz Financial Services Inc. boosted its position in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 458 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $55,000.

Supernus Pharmaceuticals Company Profile

(Get Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.